Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Mar;114(3):289-99.
doi: 10.1111/j.1471-0528.2006.01165.x. Epub 2006 Dec 12.

The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months

Magpie Trial Follow-Up Study Collaborative Group  1
Affiliations
Randomized Controlled Trial

The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months

Magpie Trial Follow-Up Study Collaborative Group. BJOG. 2007 Mar.

Abstract

Objective: To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia.

Design: Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998-2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.

Setting: Follow-up of children born at 125 centres in 19 countries across five continents.

Population: A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted.

Methods: Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.

Main outcome measures: Death or neurosensory disability at age of 18 months.

Results: Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.

Conclusions: The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort flow for children included in follow up.
Figure 2
Figure 2
Effects of treatment on death or neurosensory disability at the age of 18 months: subgroup analyses.
See this image and copyright information in PMC

References

    1. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1988;158:80–3. - PubMed
    1. The National Institute for Clinical Excellence, The Scottish Executive Health Department, The Department of Health Social Services and Public Safety Northern Ireland. Why Mothers Die 1997–1999: The Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press; 2001.
    1. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99:547–53. - PubMed
    1. Department of Health. Confidential Enquiry into Stillbirths and Deaths in Infancy. London: Department of Health; 1996.
    1. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309:1395–400. - PMC - PubMed

Publication types

MeSH terms

Associated data